Indevus Submits Nebido For Hypogonadism
This article was originally published in The Pink Sheet Daily
Executive Summary
The long-acting testosterone could offer once every 12 week dosing compared to current treatment every two to three weeks.
You may also be interested in...
Endo Gets Surprise Aveed Approval, But REMS Could Be A Roadblock
After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.
Third Time’s A Charm? Endo’s Injectable Testosterone Finally Ready For Advisory Cmte.
FDA says reports of oil embolism and anaphylactic reations with other testosterone injectables also will be part of the discussion during an April 18 meeting of the Reproductive Health Drugs and Drug Safety and Risk Management advisory committees to review Aveed (testosterone undecanoate).
Safety Fears Dog Indevus’ Testosterone Drug
New study is likely needed for Nebido approval, firm says.